SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22% SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22%

ARX Aroa Biosurgery Limited

Healthcare · Medical Devices · website
$0.49
52wk 0.47 – 0.80
Overall
48.3
Value
45.2
Growth
69.0
Health
77.8
Quality
32.8
Momentum
1.0
Dividend
—
Price
About Aroa Biosurgery Limited

Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; and Myriad Morcells, Myriad Morcells Fine, Myriad Meshed, and Symphony products for the treatment of partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds, trauma wounds, and draining wounds. The company also develops products for abdominal wall reconstruction, hernia repair, and breast reconstruction in North America and Europe. Aroa Biosurgery Limited was incorporated in 2007 and is headquartered in Auckland, New Zealand.

Price analytics

Returns

1 day 0.0%
1 week -3.9%
1 month -9.3%
3 months -14.8%
6 months -9.3%
1 year -25.8%
3 years -34.2%

Risk

Volatility (1y ann.) 49.1%
Beta vs ASX 200 0.77
Sharpe (1y) -0.44
VaR 95% (1-day) -5.1%
Max drawdown (1y) -38.4%
Off 1-year high -38.4%

Technicals

RSI(14) 30
vs 50DMA -11.3%
vs 200DMA -19.9%
Trend Death cross
Fundamental trends
Financial statements
Loading…
Scoring breakdown (2 Oct 2026)
Value 45.2
Trailing P/E
0
Forward P/E
66
PEG ratio
—
EV / EBITDA
20
Price / Book
82
Price / Sales
91
Growth 69.0
Revenue growth (1y)
64
Revenue CAGR (3y)
74
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health 77.8
Net debt / EBITDA
100
Interest coverage (EBIT/interest)
0
Current ratio
100
Debt / Equity
100
Quality (Profitability & Cash Flow) 32.8
Return on equity
24
Return on assets
31
Operating margin
48
Net margin
30
Cash conversion (OCF / net income)
—
Dividend / Income —
No meaningful dividend — pillar excluded from the overall score.
Momentum 1.0
6-month return vs ASX 200
0
Price vs 200-day average
0
Price vs 50-day average
0
Position in 52-week range
5

Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).

Score history
Key metrics
Market cap
$171.82M
P/E (trailing)
49.00
P/E (forward)
17.10
EPS (trailing)
0.01
Dividend yield
—
Payout ratio
0.0%
Beta
0.84
EV / EBITDA
16.81
Price / Book
2.11
ROE
4.9%
Operating margin
12.0%
Net margin
4.5%
Total cash
$27.14M
Total debt
$6.38M
Current ratio
4.77
Debt / Equity
0.06
Free cash flow
$6.57M
Avg volume
262,067
Latest annual results (FY ending 31 Mar 2026)
  • Revenue$86.60M
  • Gross profit$74.07M
  • Operating income-$519.51K
  • Net income$3.90M
  • Diluted EPS0.01
  • Free cash flow$5.68M
  • Net debt-$12.25M
Sector peers (Healthcare)
TickerMkt cap P/EScore
CSL $84.15B — 54.3
RMD $45.86B 21.2 74.4
SIG $29.91B 43.3 55.6
FPH $21.64B 57.5 71.1
PME $16.34B 61.8 69.0
RHC $12.56B 40.0 40.2
SHL $9.12B 15.0 43.0
COH $8.20B 55.5 39.4